Legislation being marked up in the U.S. House today could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP). | Shutterstock

House Set To Act on Bill that Could Result in Higher Medicaid Rebates and 340B Discounts

In Federal, LegislativeFebruary 11, 202136 Views

Tom Mirga

The U.S. House Energy and Commerce Committee is scheduled to mark up COVID-19 relief legislation today with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP).

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden

*Sign up for news summaries and alerts from 340B Report